Medicamen Biotech Limited
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Medicamen Biotech Limited's past years’ income statements indicate that its last revenue has increased compared to the previous period by 55% to $1,793,062,000. Profit margin reached 6%. Total operating expenses were $335,167,000.

Profit Margin

Medicamen Biotech Limited (NSE:MEDICAMEQ.NS): Profit margin
2012 1.00B -8.24M -0.82%
2015 777.93M 4.40M 0.57%
2016 672.75M 4.80M 0.71%
2018 1.11B 101.12M 9.07%
2019 1.22B 120.25M 9.81%
2021 1.12B 121.29M 10.76%
2022 1.15B 148.97M 12.9%
2024 1.79B 109.31M 6.1%

MEDICAMEQ.NS Income Statement (2012 – 2023)

2023 2021 2020 2018 2017 2015 2014 2012
Revenue
Revenue
1.79B1.15B1.12B1.22B1.11B672.75M777.93M1.00B
Cost of revenue
941.05M674.57M791.99M911.88M787.82M488.62M582.38M801.48M
Gross profit
852.01M479.87M335.16M314.15M327.24M184.13M195.55M203.78M
Operating exp.
Research and development
010.51M6.85M2.99M5.55M1.84M1.33M0
Selling and marketing
27.52M32.37M5.96M8.92M14.80M24.15M25.61M0
Total operating expenses
335.16M289.88M160.41M159.68M179.86M147.81M165.80M196.63M
Operating income
516.84M178.95M168.25M154.47M147.38M7.11M1.17M-6.55M
Other income (expenses), net
-386.08M1.99M-149.46M20.75M-8.38M-29.26M-28.23M122.39K
Income before tax
130.75M180.94M163.94M175.22M139.00M7.11M1.20M-6.43M
Income tax expense
35.81M31.97M42.64M54.96M37.87M2.30M-3.19M1.81M
Net income
109.31M148.97M121.29M120.25M101.12M4.80M4.40M-8.24M
Earnings per share
Basic EPS
8.6312.199.9310.289.030.480.49-1.04
Diluted EPS
8.6312.199.9310.289.030.480.49-1.04
Data sourceData sourceData sourceData sourceData sourceData sourceData sourceData source